A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
He noted its use in Ancient Rome in religious ceremonies to purify homes by fumigation (something also briefly evoked in a line of Ovid's Ars Amatoria about purifying houses with eggs and sulfur). The use of sulfur for fumigation is very ancient and was already a practice in preclassical Greece; this is mentioned in the Odyssey. Several Roman authors of the second half of the first century, such as Martial and Statius, reference a type of street trade seemingly common at the time, where peddlers in the streets would exchange pieces of sulfur or sulfur "matches" (actually some kind of sulfured wooden splints used as a fire starter, rather than friction matches) for broken glass. The Persian army used sulfur as a chemical weapon during the siege of Dura-Europos, in the 3rd century. They burned pitch and sulfur in tunnels, creating a toxic cloud of sulfur dioxide which killed the Roman soldiers in the tunnels. A natural form of sulfur known as shiliuhuang (Chinese: 石硫黃; pinyin: shí liú huáng) was known in China since the 6th century BC and found in Hanzhong. By the 3rd century, the Chinese had discovered that sulfur could be extracted from pyrite. Chinese Daoists were interested in sulfur's flammability and its reactivity with certain metals, yet its earliest practical uses were found in traditional Chinese medicine.
Homotropic allosteric enzymes: substrate and effector play a part in the modulation of the enzyme, which affects the enzyme catalytic activity. Heterotropic allosteric enzymes: only the effector performs the role of modulation.
New Orleans Cold Storage and Warehouse Co. is an American company providing refrigerated warehousing in the US port cities of New Orleans, Houston and Charleston. Facilities include refrigerated storage and blast freezing, and they maintain USDA and foreign export certifications for meat and poultry.
I have been frequently asked why I invented the name "Penicillin". I simply followed perfectly orthodox lines and coined a word which explained that the substance penicillin was derived from a plant of the genus Penicillium just as many years ago the word "Digitalin" was invented for a substance derived from the plant Digitalis. For the effect on the cultures of staphylococci that Fleming observed, the mould had to be growing before the bacteria began to grow, because penicillin is only effective on bacteria when they are reproducing. Fortuitously, the temperature in the laboratory during that August was optimum first for the growth of the mould, below 20 °C (68 °F), and later in the month for the bacteria, when it reached 25 °C (77 °F). Had Fleming not left the cultures on his laboratory bench and put them in an incubator, the phenomenon would not have occurred. Fleming had no training in chemistry; he left all the chemical work to Craddock, once remarking "I am a bacteriologist, not a chemist." In January 1929, he recruited Frederick Ridley, his former research scholar who had studied biochemistry, specifically to study the chemical properties of the mould. But they could not isolate penicillin, and before the experiments were over, Craddock and Ridley both left Fleming for other jobs. It was due to his failure to isolate the compound that Fleming practically abandoned further research on the chemical aspects of penicillin.
The biotechnical company Defymed, based in France, is developing an implantable bio-artificial device called MailPan which features a bio-compatible membrane with selective permeability to encapsulate different cell types, including pancreatic beta cells. The implantation of the device does not require conjunctive immuno-suppressive therapy because the membrane prevents antibodies of the patient from entering the device and damaging the encapsulated cells. After being surgically implanted, the membrane sheet will be viable for years. The cells that the device holds can be produced from stem cells rather than human donors, and may also be replaced over time using input and output connections without surgery. Defymed is partially funded by JDRF, formerly known as the Juvenile Diabetes Research Foundation, but is now defined as an organization for all ages and all stages of type 1 diabetes. In November 2018, it was announced that Defymed would partner with the Israel-based Kadimastem, a bio-pharmaceutical company developing stem-cell based regenerative therapies, to receive a two-year grant worth approximately $1.47 million for the development of a bio-artificial pancreas that would treat type 1 diabetes. Kadimastem's stem cell technology uses differentiation of human embryonic stem cells to obtain pancreatic endocrine cells. These include insulin-producing beta cells, as well as alpha cells, which produce glucagon. Both cells arrange in islet-like clusters, mimicking the structure of the pancreas.
Sources: en.wikipedia.org
=== Viral inhibitors === Influenza viruses are mainly spread from person to person through airborne droplets produced while coughing or sneezing. However, the viruses can also be transmitted when a person touches respiratory droplets settled on an object or surface. It is during this stage that an antiviral surface could play the biggest role in cutting down on the spread of a virus. Glass slides painted with the hydrophobic long-chained polycation N,N dodecyl,methyl-polyethylenimine (N,N-dodecyl,methyl-PEI) are highly lethal to waterborne influenza A viruses, including not only wild-type human and avian strains but also their neuraminidase mutants resistant to anti-influenza drugs. Copper alloy surfaces have been investigated for their antiviral efficacies. After incubation for one hour on copper, active influenza A virus particles were reduced by 75%. After six hours, the particles were reduced on copper by 99.999%. Also, 75% of Adenovirus particles were inactivated on copper (C11000) within 1 hour. Within six hours, 99.999% of the adenovirus particles were inactivated.
Carbon nanotubes: Carbon materials have a wide range of uses, ranging from composites for use in vehicles and sports equipment to integrated circuits for electronic components. The interactions between nanomaterials such as carbon nanotubes and natural organic matter strongly influence both their aggregation and deposition, which strongly affects their transport, transformation, and exposure in aquatic environments. In past research, carbon nanotubes exhibited some toxicological impacts that will be evaluated in various environmental settings in current EPA chemical safety research. EPA research will provide data, models, test methods, and best practices to discover the acute health effects of carbon nanotubes and identify methods to predict them. Cerium oxide: Nanoscale cerium oxide is used in electronics, biomedical supplies, energy, and fuel additives. Many applications of engineered cerium oxide nanoparticles naturally disperse themselves into the environment, which increases the risk of exposure. There is ongoing exposure to new diesel emissions using fuel additives containing CeO2 nanoparticles, and the environmental and public health impacts of this new technology are unknown. EPA's chemical safety research is assessing the environmental, ecological, and health implications of nanotechnology-enabled diesel fuel additives. Titanium dioxide: Nano titanium dioxide is currently used in many products. Depending on the type of particle, it may be found in sunscreens, cosmetics, and paints and coatings.
Committee on Armed Services Subcommittee on Cybersecurity Subcommittee on Emerging Threats and Capabilities Subcommittee on Seapower Committee on Commerce, Science, and Transportation Subcommittee on Space and Science (Ranking Member) Subcommittee on Communications, Media, and Broadband Subcommittee on Surface Transportation, Maritime, Freight, and Ports
=== Chronic fatigue syndrome === Chronic fatigue syndrome (CFS) is a debilitating illness, the cause of which is unknown. Patients with CFS have abnormal neurological, immunological, and metabolic findings. For many, but not all, patients who meet criteria for CFS, the illness begins with an acute, infectious-like syndrome. Cases of CFS can follow well-documented infections with several infectious agents. A study of 259 patients with a "CFS-like" illness published shortly after HHV-6 was discovered used primary lymphocyte cultures to identify people with active replication of HHV-6. Such active replication was found in 70% of the patients vs. 20% of the control subjects (
Sources: en.wikipedia.org
The 25 April 1953 issue of the journal Nature published a series of five articles giving the Watson and Crick double-helix structure DNA and evidence supporting it. The structure was reported in a letter in which they stated, "It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material." This letter was followed by a letter from Franklin and Gosling, which was the first publication of their own X-ray diffraction data and of their original analysis method. Then followed a letter by Wilkins and two of his colleagues, which contained an analysis of in vivo B-DNA X-ray patterns, and which supported the presence in vivo of the Watson and Crick structure. In April 2023, scientists, based on new evidence, concluded that Rosalind Franklin was a contributor and "equal player" in the discovery process of DNA, rather than otherwise, as may have been presented subsequently after the time of the discovery. In 1962, after Franklin's death, Watson, Crick, and Wilkins jointly received the Nobel Prize in Physiology or Medicine. Nobel Prizes are awarded only to living recipients. A debate continues about who should receive credit for the discovery. In an influential presentation in 1957, Crick laid out the central dogma of molecular biology, which foretold the relationship between DNA, RNA, and proteins, and articulated the "adaptor hypothesis". Final confirmation of the replication mechanism that was implied by the double-helical structure followed in 1958 through the Meselson–Stahl experiment.
The law of conservation of vis viva was championed by the father and son duo, Johann and Daniel Bernoulli. The former enunciated the principle of virtual work as used in statics in its full generality in 1715, while the latter based his Hydrodynamica, published in 1738, on this single vis viva conservation principle. Daniel's study of loss of vis viva of flowing water led him to formulate Bernoulli's principle, which asserts the loss to be proportional to the change in hydrodynamic pressure. Daniel also formulated the notion of work and efficiency for hydraulic machines; and he gave a kinetic theory of gases, and linked the kinetic energy of gas molecules with the temperature of the gas. This focus on the vis viva by the continental physicists eventually led to the discovery of stationarity principles governing mechanics, such as the D'Alembert's principle, Lagrangian, and Hamiltonian formulations of mechanics.
In response, the corporation aggressively executed a $200 million structural cost take-out program to mitigate rising supply chain costs and volatile tariff headwinds. Despite these efforts, annual net sales for fiscal 2025 fell to $15.52 billion, down from $16.60 billion in 2024. To stimulate demand, the company launched its largest pipeline of new product refreshes in over a decade, introducing more than 100 new appliances globally across its core brands, including KitchenAid, JennAir, and Maytag. In February 2026, Whirlpool announced a strategic recapitalization plan, launching concurrent public offerings of common stock and depositary shares totaling approximately $800 million. The net proceeds were aimed at deleveraging its balance sheet by paying down outstanding balances under its revolving credit facility and accelerating strategic investments in manufacturing automation. However, the company faced severe financial pressure in early 2026 due to rapid macroeconomic deterioration, shifting tariff landscapes, and high inventory reduction costs. In May 2026, Whirlpool reported a first-quarter GAAP net loss of $85 million, a steep reversal from the prior year's net earnings. To combat multi-year inflationary cost pressures, management announced a 10% domestic price increase in April 2026—its largest pricing action in a decade—with an additional 4% hike scheduled for July 2026.
In his third year of medical school Banting successfully joined the Royal Canadian Army Medical Corps in 1915 and was commissioned a private, then promoted to sergeant. He trained at a camp at Niagara Falls for the summer before his fourth year of school. The university accelerated the class by condensing the fifth year of medical school during the summer of 1916. The curriculum emphasized surgical procedure and trauma; a lecture dedicated to the treatment of diabetes derived itself from Frederick Madison Allen of the Rockefeller Institute, who recommended that diabetics be placed on a starvation diet for minimum metabolization. Banting's fourth year was committed to clinical work at Toronto General Hospital. Under the guidance of Clarence L. Starr, the chief surgeon at the Hospital for Sick Children, Banting gained training as an undergraduate house surgeon. By 1915, he had definitively resolved to practice surgery, performing his first operation—the drainage of a soldier's abscess—next winter. On December 9, 1916, Banting graduated with his Bachelor of Medicine (M.B.) and reported for military duty the next day. After being promoted to lieutenant, he sailed from Halifax to Britain on March 26, 1917. Shortly before departing he became engaged to Edith Roach, whom he met in 1911. Starr, an orthopedist who enlisted in 1916, had been impressed by Banting's work as an undergraduate and requested that he join him at the Granville Canadian Special Hospital in Ramsgate, Kent. On May 2, 1917, Banting assumed a position as Starr's assistant.
== Career == In early 1964, Sarkar presented his PhD research at the Federation of American Societies for Experimental Biology (FASEB) meeting in Chicago, where he was approached by Andrew Sass-Kortsak, a clinician specializing in Wilson's disease at Toronto's Hospital for Sick Children. Sass-Kortsak, then leading the hospital's Genetic Metabolic Program, sought a basic scientist to join his team and offered Sarkar a staff scientist position. This role included start-up funding and a dedicated laboratory in a newly constructed wing of the hospital. Shortly after, Sarkar received a cross-appointment to the University of Toronto's Department of Biochemistry. Sarkar began attending clinical Grand Rounds with Sass-Kortsak and visited Wilson's disease patients in hospital wards. His research shifted toward metal-related disorders, driven by his expertise in biophysical studies of metal-protein interactions and metal transport. Collaborating with Sass-Kortsak, Sarkar pioneered multidisciplinary research at SickKids, bridging basic science and clinical medicine to foster a collaborative institutional environment. In 1990, he was appointed head of the Division of Biochemistry Research at SickKids.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.